Novartis Venture Fund returned as GentiBio raised money that will support the progress of its type 1 diabetes drug candidate toward clinical trials.
US-based immunology therapy developer GentiBio has completed a $157m series A round featuring pharmaceutical firm Novartis, which invested through its Novartis Venture Fund.
Investment manager Matrix Capital Management led the round, which included Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management and Seattle Children’s Research Institute.
GentiBio is engineering specialised regulatory T cells (Tregs) that will form the basis of therapeutics for autoimmune, alloimmune, autoinflammatory and allergic diseases where tissue has been damaged by abnormal immune responses.
The series…
